Cerebral Visual ImpairmentBiGNCT05048550
Babies in Glasses; a Feasibility Study.
A study testing Near vision spectacles in people with Cerebral Visual Impairment and Refractive and Accommodative Disorders, run by Great Ormond Street Hospital for Children NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
This is a feasibility study to begin investigating the possibility that early use of near vision glasses will improve vision in infants at risk of Cerebral Visual Impairment (CVI), leading to further improvement in other areas of development. Read more about this study
- Who is it for?
- Ages Up to 8 weeks
- Conditions the study is for
- Cerebral Visual Impairment, Refractive and Accommodative Disorders, Hypoxic-Ischemic Encephalopathy
- What is being tested?
- Near vision spectacles
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 9 Sep 2021to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 8 weeks
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- All term infants undergoing therapeutic hypothermia for hypoxic ischaemic encephalopathy (HIE).
- All preterm infants born at <29 weeks gestational age.
- Specifically, all children fulfilling these criteria will be eligible. Evidence of hypo-accommodation is not required.
Who cannot join
- Infants that are still an inpatient at 8 weeks corrected gestational age.
- Ocular exclusion criteria: children with unrelated congenital or developmental ocular abnormality such as cataract requiring surgery, genetic retinal disease, coloboma. Retinopathy of prematurity will not be an exclusion criterion.
- Infants with high refractive error (more than -6.00D spherical equivalent or +8.00D spherical equivalent).
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University College London Hospital
London, WC1E 6DB
About this study
Official title: Can Provision of Near Vision Glasses as an Early Intervention Improve Visual and Developmental Outcomes in Children With Perinatal Brain Insult? A Feasibility Study.
This is a feasibility study to begin investigating the possibility that early use of near vision glasses will improve vision in infants at risk of Cerebral Visual Impairment (CVI), leading to further improvement in other areas of development. This active intervention, starting at either 2 or 4 months of age (depending on randomisation), could be more effective than waiting until a problem is detected before giving glasses.
As this is a feasibility study, the investigators are looking at a small sample of babies (n=75) to see whether their parents/carers are willing to take part in a 3-arm study comparing two differently timed interventions to a control group, as well as looking at different aspects of the research plan in preparation for a larger final study.
Read the detailed description
The aim of this study is to assess the feasibility and the acceptability of randomisation and the intervention, namely near vision glasses, from parents of very young babies at risk of Cerebral Visual Impairment (CVI).
All infants are born with an immature visual system, and for vision to develop normally, a clear image needs to transmit to the visual centres of the brain.
Good vision plays an important role in facilitating normal development so if CVI goes unnoticed, it can have a damaging effect on the child's early development, and subsequent education and quality of life. Children use their sight to learn to walk, talk, think and communicate. For this reason, early intervention has the potential to have positive effects on children's vision and general development.
Previous studies have shown that up to 75% of school age children, who have CVI, have difficulty focussing their eyes on a near target, so near objects, such as their hands and parents' faces, will appear blurry. These studies also showed that wearing glasses for near focus improved vision but has not been assessed in babies.
This is a single-centre, parallel group, open-label feasibility trial to assess the feasibility of testing the effect near vision glasses (full cycloplegic refraction plus 3.00D add for near) could have on the visual and developmental outcome in babies at risk of brain injury.
Infants at risk of developing CVI include those who have had hypoxic ischaemic encephalopathy (HIE) and those born prematurely before 29 weeks gestation.
The paediatric research optometrist will enrol and assess all eligible babies of consenting families; first visit at 8 or 16 weeks corrected gestational age, depending on randomisation. Each infant will be followed up 3 months and 6-months (+/- 3 weeks) after the first visit.
There are three main areas of the assessment, which will be leading to potential primary outcome measures:
- Visual Responses (including visual acuity and refractive status) At each visit, vision will be evaluated using Atkinson's battery for Child Development for Examining Functional Vision (ABCDEFV) according to the child's age and their ability. This comprises age-appropriate core vision tests (such as visual acuity and fixing and following) as well as additional tests that assess visual perception and visuomotor behaviour. If visual acuity cannot be obtained using Keeler acuity cards, as per ABCDEFV, the children will receive a measure using a Near Detection Scale (NDS).
- General Development and Neurodevelopmental Delay Non-visual developmental assessments will include the Bayley Scales of Infant Development - 3rd edition (BSID-III) assessment as appropriate for age at routine neonatal clinical appointments at 3, 6,12 and 24 months (not the research clinics). A Prechtl video will also be performed at the 3-month appointment to assess the presence of fidgety movements. The presence of these movements at 3 months corrected gestational age has been strongly correlated with normal motor development.
- Functional broadband near infrared spectroscopy (fBNIRS)
- Identification of changed functional haemodynamic and metabolic response to visual stimulus in infants at risk of visual dysfunction. ii. Assessment of changes in functional response in relation to response to glasses Eligible children with consenting parents will be screened for high refractive error prior to randomisation by the research optometrist to avoid post-randomisation dropouts. Evidence of high refractive error (more than -6.00D spherical equivalent or +8.00D spherical equivalent) will result in a referral to ophthalmology and exclusion from the study due to the possibility of associated ocular pathology with high refractive error. All of the above assessments have been organised at University College London Hospitals (UCLH). If the infant is randomised to get glasses, they will be given a near vision spectacle prescription (full cycloplegic refraction plus 3.00D add for near) to take to Great Ormond Street Hospital Eye Department dispensing optician to get the special glasses ordered. Expert ethical advice has been sought through the NIHR's Research Design Service to check on the dimension of potential harm (with a positive review). Each case will be monitored by the independent data monitoring and ethics committee (IDMEC) using follow up data who will report to the trial steering committee (TSC). The IDMEC, Trial Steering Committee (TSC) and Trial Management Group (TMG) will oversee the conduct of this trial.
- Conditions
- Cerebral Visual Impairment, Refractive and Accommodative Disorders, Hypoxic-Ischemic Encephalopathy, Premature Birth
- Being tested
- Near vision spectacles
- Keywords
- Cerebral Visual Impairment, CVI, Visual Processing Disorder, Visual Perceptual Deficits, VPD, Accommodative Disorders, Hypo-accommodation, Accommodative lag, Hypoxic Ischaemic Encephalopathy, Premature Birth, Near Vision Glasses, Spectacle correction, Refractive correction, Refractive Error, Early spectacle correction, Spectacles, Glasses, Perinatal Brain Insult, Brain Injury, Neurodevelopment
- Medical subject headings
- Blindness, Cortical, Hypoxia-Ischemia, Brain, Premature Birth, Refractive Errors, Brain Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Near vision spectaclesDevice
Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
| Study group | Role | What they receive |
|---|---|---|
| A (control) | No intervention | First visit assessments at 8 weeks corrected gestational age. No glasses prescribed. |
| B1 (intervention) | Experimental | First visit assessments at 8 weeks corrected gestational age. Full time spectacle wear prescribed. Receives: Device: Near vision spectacles |
| B2 (intervention) | Experimental | First visit assessments at 16 weeks corrected gestational age. Full time spectacle wear prescribed. Receives: Device: Near vision spectacles |
What is being measured
The primary outcome is the main question the study is designed to answer.
The acceptance of randomisation
This will be measured as the proportion of patients/parents who accept the offer of randomisation.
Measured: 10 months
Secondary outcomes (11)
Success rate in dispensing glasses to children in groups B1 and B2.
The percentage of infants dispensed vs. the total number of infants randomised to the intervention arms will be recorded at the end of the study.
Measured: 6 months
Success rate of compliance with glasses for infants in groups B1 and B2.
The proportion of infants (%) who are still wearing their glasses at the 3 and 6 month follow-up appointments.
Measured: 6 months
Visual Acuity
The distribution of visual acuity at the 3 and 6-month follow ups compared with visual acuity at the first visit in all 3 arms.
Measured: 6 months
Retention rate
This will be measured by the median number of infants reported per month.
Measured: 15 months
Refractive outcomes
The distribution of refractive outcomes (measured in dioptres) at 3 and 6-month follow ups as compared to the first visit in all 3 groups.
Measured: 6 months
Evidence of impaired emmetropisation following administration of FMT
This will be measured by combining refractive error and visual acuity measures. The trial will not be feasible if there is a 2SD difference without compensatory benefit eg 2 lines improvement in visual acuity.
Measured: 6 months
Determination of appropriate resource-use data collection methods
A targeted paediatric client service receipt inventory (CSRI) form has been designed specifically for this population and will be used for the duration of the feasibility study.
Measured: 15 months
Accommodative outcomes
The distribution of accommodative outcomes (measured in dioptres) at 3 and 6-month follow ups as compared to the first visit in all 3 groups.
Measured: 6 months
Completion of compliance questionnaires
Proportion of families completing phone questionnaire on spectacle compliance as a percentage of those in the intervention groups (B1 \& B2).
Measured: 6 months
Significant mechanical trauma
Significant mechanical trauma will be measured as the percentage of infants who have had an adverse event (from mechanical trauma) vs. the total number of infants prescribed glasses in groups B1 and B2. The study will not be feasible if this is more than 30% of infants in the intervention arms.
Measured: 6 months
Consent rate
This will be measured as the number of infants recruited vs. number of infants, who fulfil the inclusion/exclusion criteria, approached.
Measured: 10 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2021
- Study start9 Sep 2021
- Primary completion9 Jun 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cerebral Visual ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a single-centre randomised interventional study; a 3-arm parallel group, open-label clinical feasibility trial for a definitive RCT with equal arm allocation and a superiority design.
- Masking
- None (open label)
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom, University College London Hospitals, University College, London, University of Reading, University of Bristol, University of Ulster
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05048550
- Sponsor's protocol ID
- 18BA36
- Acronym
- BiG
- Status last verified
- Sep 2022
- First submitted
- 24 Jun 2021
- Last updated
- 29 Sep 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Bullaj R, Dyet L, Mitra S, Bunce C, Clarke CS, Saunders K, Dale N, Horwood A, Williams C, St Clair Tracy H, Marlow N, Bowman R. Can provision of near vision glasses as an early intervention improve visual outcomes in infants at risk of perinatal brain insult? The Babies in Glasses (BiG) randomised feasibility trial. BMJ Open. 2026 Feb 16;16(2):e107894. doi: 10.1136/bmjopen-2025-107894.
PubMed 41698720Bullaj R, Dyet L, Mitra S, Bunce C, Clarke CS, Saunders K, Dale N, Horwood A, Williams C, St Clair Tracy H, Marlow N, Bowman R. Effectiveness of early spectacle intervention on visual outcomes in babies at risk of cerebral visual impairment: a parallel group, open-label, randomised clinical feasibility trial protocol. BMJ Open. 2022 Sep 21;12(9):e059946. doi: 10.1136/bmjopen-2021-059946.
PubMed 36130761
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Can Provision of Near Vision Glasses as an Early Intervention Improve Visual and Developmental Outcomes in Children With Perinatal Brain Insult? A Feasibility Study.
- ClinicalTrials.gov ID
- NCT05048550
- Acronym / sponsor ID
- BiG / 18BA36
- Conditions
- Cerebral Visual Impairment, Refractive and Accommodative Disorders, Hypoxic-Ischemic Encephalopathy, Premature Birth
- Keywords
- Cerebral Visual Impairment, CVI, Visual Processing Disorder, Visual Perceptual Deficits, VPD, Accommodative Disorders, Hypo-accommodation, Accommodative lag
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 55 participants (actual)
- Lead sponsor
- Great Ormond Street Hospital for Children NHS Foundation TrustUniversity, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom, University College London Hospitals, University College, London, University of Reading, University of Bristol, University of Ulster
- Study start
- 9 Sep 2021 (actual)
- Primary completion
- 9 Jun 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 17 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a feasibility study to begin investigating the possibility that early use of near vision glasses will improve vision in infants at risk of Cerebral Visual Impairment (CVI), leading to further improvement in other areas of development. This active intervention, starting at either 2 or 4 months of age (depending on randomisation), could be more effective than waiting until a problem is detected before giving glasses.
As this is a feasibility study, the investigators are looking at a small sample of babies (n=75) to see whether their parents/carers are willing to take part in a 3-arm study comparing two differently timed interventions to a control group, as well as looking at different aspects of the research plan in preparation for a larger final study.
Detailed description
The aim of this study is to assess the feasibility and the acceptability of randomisation and the intervention, namely near vision glasses, from parents of very young babies at risk of Cerebral Visual Impairment (CVI).
All infants are born with an immature visual system, and for vision to develop normally, a clear image needs to transmit to the visual centres of the brain.
Good vision plays an important role in facilitating normal development so if CVI goes unnoticed, it can have a damaging effect on the child's early development, and subsequent education and quality of life. Children use their sight to learn to walk, talk, think and communicate. For this reason, early intervention has the potential to have positive effects on children's vision and general development.
Previous studies have shown that up to 75% of school age children, who have CVI, have difficulty focussing their eyes on a near target, so near objects, such as their hands and parents' faces, will appear blurry. These studies also showed that wearing glasses for near focus improved vision but has not been assessed in babies.
This is a single-centre, parallel group, open-label feasibility trial to assess the feasibility of testing the effect near vision glasses (full cycloplegic refraction plus 3.00D add for near) could have on the visual and developmental outcome in babies at risk of brain injury.
Infants at risk of developing CVI include those who have had hypoxic ischaemic encephalopathy (HIE) and those born prematurely before 29 weeks gestation.
The paediatric research optometrist will enrol and assess all eligible babies of consenting families; first visit at 8 or 16 weeks corrected gestational age, depending on randomisation. Each infant will be followed up 3 months and 6-months (+/- 3 weeks) after the first visit.
There are three main areas of the assessment, which will be leading to potential primary outcome measures:
- Visual Responses (including visual acuity and refractive status) At each visit, vision will be evaluated using Atkinson's battery for Child Development for Examining Functional Vision (ABCDEFV) according to the child's age and their ability. This comprises age-appropriate core vision tests (such as visual acuity and fixing and following) as well as additional tests that assess visual perception and visuomotor behaviour. If visual acuity cannot be obtained using Keeler acuity cards, as per ABCDEFV, the children will receive a measure using a Near Detection Scale (NDS).
- General Development and Neurodevelopmental Delay Non-visual developmental assessments will include the Bayley Scales of Infant Development - 3rd edition (BSID-III) assessment as appropriate for age at routine neonatal clinical appointments at 3, 6,12 and 24 months (not the research clinics). A Prechtl video will also be performed at the 3-month appointment to assess the presence of fidgety movements. The presence of these movements at 3 months corrected gestational age has been strongly correlated with normal motor development.
- Functional broadband near infrared spectroscopy (fBNIRS)
- Identification of changed functional haemodynamic and metabolic response to visual stimulus in infants at risk of visual dysfunction. ii. Assessment of changes in functional response in relation to response to glasses Eligible children with consenting parents will be screened for high refractive error prior to randomisation by the research optometrist to avoid post-randomisation dropouts. Evidence of high refractive error (more than -6.00D spherical equivalent or +8.00D spherical equivalent) will result in a referral to ophthalmology and exclusion from the study due to the possibility of associated ocular pathology with high refractive error. All of the above assessments have been organised at University College London Hospitals (UCLH). If the infant is randomised to get glasses, they will be given a near vision spectacle prescription (full cycloplegic refraction plus 3.00D add for near) to take to Great Ormond Street Hospital Eye Department dispensing optician to get the special glasses ordered. Expert ethical advice has been sought through the NIHR's Research Design Service to check on the dimension of potential harm (with a positive review). Each case will be monitored by the independent data monitoring and ethics committee (IDMEC) using follow up data who will report to the trial steering committee (TSC). The IDMEC, Trial Steering Committee (TSC) and Trial Management Group (TMG) will oversee the conduct of this trial.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- This is a single-centre randomised interventional study; a 3-arm parallel group, open-label clinical feasibility trial for a definitive RCT with equal arm allocation and a superiority design.
| Arm | Type | Receives |
|---|---|---|
| A (control) | No intervention | –First visit assessments at 8 weeks corrected gestational age. No glasses prescribed. |
| B1 (intervention) | Experimental | Device: Near vision spectaclesFirst visit assessments at 8 weeks corrected gestational age. Full time spectacle wear prescribed. |
| B2 (intervention) | Experimental | Device: Near vision spectaclesFirst visit assessments at 16 weeks corrected gestational age. Full time spectacle wear prescribed. |
Who may qualify
- Ages
- Up to 8 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- All term infants undergoing therapeutic hypothermia for hypoxic ischaemic encephalopathy (HIE).
- All preterm infants born at <29 weeks gestational age.
- Specifically, all children fulfilling these criteria will be eligible. Evidence of hypo-accommodation is not required.
Key exclusion criteria (3 listed)
- Infants that are still an inpatient at 8 weeks corrected gestational age.
- Ocular exclusion criteria: children with unrelated congenital or developmental ocular abnormality such as cataract requiring surgery, genetic retinal disease, coloboma. Retinopathy of prematurity will not be an exclusion criterion.
- Infants with high refractive error (more than -6.00D spherical equivalent or +8.00D spherical equivalent).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Near vision spectaclesNear vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up. | Device | B1 (intervention), B2 (intervention) |
Primary outcome
The acceptance of randomisation
Time frame: 10 months
This will be measured as the proportion of patients/parents who accept the offer of randomisation.
11 secondary outcomes
Success rate in dispensing glasses to children in groups B1 and B2.
Time frame: 6 months
Success rate of compliance with glasses for infants in groups B1 and B2.
Time frame: 6 months
Visual Acuity
Time frame: 6 months
Retention rate
Time frame: 15 months
Refractive outcomes
Time frame: 6 months
Evidence of impaired emmetropisation following administration of FMT
Time frame: 6 months
Determination of appropriate resource-use data collection methods
Time frame: 15 months
Accommodative outcomes
Time frame: 6 months
Completion of compliance questionnaires
Time frame: 6 months
Significant mechanical trauma
Time frame: 6 months
Consent rate
Time frame: 10 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2022.
- Derived from this study: PubMed 41698720Bullaj R, Dyet L, Mitra S, Bunce C, Clarke CS, Saunders K, Dale N, Horwood A, Williams C, St Clair Tracy H, Marlow N, Bowman R. Can provision of near vision glasses as an early intervention improve visual outcomes in infants at risk of perinatal brain insult? The Babies in Glasses (BiG) randomised feasibility trial. BMJ Open. 2026 Feb 16;16(2):e107894. doi: 10.1136/bmjopen-2025-107894.
- Derived from this study: PubMed 36130761Bullaj R, Dyet L, Mitra S, Bunce C, Clarke CS, Saunders K, Dale N, Horwood A, Williams C, St Clair Tracy H, Marlow N, Bowman R. Effectiveness of early spectacle intervention on visual outcomes in babies at risk of cerebral visual impairment: a parallel group, open-label, randomised clinical feasibility trial protocol. BMJ Open. 2022 Sep 21;12(9):e059946. doi: 10.1136/bmjopen-2021-059946.
Related trials for Cerebral Visual Impairment
Not yet recruiting
joyVision: The Superiority of Co-design in the Development of a Serious Game for Children With Cerebral Visual Impairment
Cerebral Visual Impairment
Not yet recruiting
Ameliorating Stroke-induced Hemianopia Via Multisensory Training
Hemianopia, Homonymous, Cortical Blindness, Unspecified Side of Brain
Active, not recruiting
Statistical Learning as a Novel Intervention for Cortical Blindness
Stroke, Ischemic, Hemianopia, Homonymous
Not yet recruiting
SENSE-Brain Health Pro for Older Adults With Sensory Loss
Vision and Hearing Loss, Vision Impairment
Enrolling by invitationObservational study
Visual Impairment and Functional Visual Performance Following Acquired Brain Injury: A Cross-Sectional Study
Vision Disorder, Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Near vision spectacles in people with Cerebral Visual Impairment and Refractive and Accommodative Disorders, run by Great Ormond Street Hospital for Children NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The acceptance of randomisation (time frame: 10 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05048550, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2022.